Jean-François Schved

Jean-François Schved

Auto-generated profile, based on publicly available information

Jean-François Schved

Hemophilia Treatment Center, Montpellier University Hospital, Montpellier, France

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
CCCaroline Charlier
Caroline Charlier
ÉPÉlodie Perrodeau
Élodie Perrodeau
Alexandre LeclercqAlexandre Leclercq
Alexandre Leclercq
BCBenoît Cazenave
Benoît Cazenave
BPBenoît Pilmis
Benoît Pilmis
CZChristian Zumbo
Christian Zumbo
Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its clinical features and prognostic factors. MONALISA was a national prospective observational cohort study. We enrolled eligible cases declared to the National Reference Center for Listeria (all microbiologically proven) between Nov 3, 2009, and July 31, 2013, in the context of mandatory reporting. The outcomes were analysis of clinical features, characterisation of Listeria isolates, and determination of predictors of 3-month mortality or persisting impairment using logistic regression. A hierarchical clustering on principal components was also done for neurological and bacteraemic cases. The study is registered at ClinicalTrials.gov, number NCT01520597. We enrolled 818 cases from 372 centres, including 107 maternal-neonatal infections, 427 cases of bacteraemia, and 252 cases of neurolisteriosis. Only five (5%) of 107 pregnant women had an uneventful outcome. 26 (24%) of 107 mothers experienced fetal loss, but never after 29 weeks of gestation or beyond 2 days of admission to hospital. Neurolisteriosis presented as meningoencephalitis in 212 (84%) of 252 patients; brainstem involvement was only reported in 42 (17%) of 252 patients. 3-month mortality was higher for bacteraemia than neurolisteriosis (hazard ratio [HR] 0·54 [95% CI 0·41-0·69], p<0·0001). For both bacteraemia and neurolisteriosis, the strongest mortality predictors were ongoing cancer (odds ratio [OR] 5·19 [95% CI 3·01-8·95], p<0·0001), multi-organ failure (OR 7·98 [4·32-14·72], p<0·0001), aggravation of any pre-existing organ dysfunction (OR 4·35 [2·79-6·81], p<0·0001), and monocytopenia (OR 3·70 [1·82-7·49], p=0·0003). Neurolisteriosis mortality was higher in blood-culture positive patients (OR 3·67 [1·60-8·40], p=0·002) or those receiving adjunctive dexamethasone (OR 4·58 [1·50-13·98], p=0·008). The severity of listeriosis is higher than reported elsewhere. We found evidence of a significantly reduced survival in patients with neurolisteriosis treated with adjunctive dexamethasone, and also determined the time window for fetal losses. MONALISA provides important new data to improve management and predict outcome in listeriosis. Programme Hospitalier Recherche Clinique, Institut Pasteur, Inserm, French Public Health Agency.

9 February 2012 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
FPFlora Peyvandi
Flora Peyvandi
RPR. Palla
R. Palla
MMM. Menegatti
M. Menegatti
SSS. M. Siboni
S. M. Siboni
SHS. Halimeh
S. Halimeh
OGON BEHALF OF THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN‐RBD) GROUP
ON BEHALF OF THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN‐RBD) GROUP
Summary. Background: The European Network of Rare Bleeding Disorders (EN‐RBD) was established to bridge the gap between knowledge and practise in the care of patients with RBDs. Objectives: To explore the relationship between coagulation factor activity level and bleeding severity in patients with RBDs. Patients/Methods: Cross‐sectional study using data from 489 patients registered in the EN‐RBD. Coagulation factor activity levels were retrieved. Clinical bleeding episodes were classified into four categories according to severity. Results: The mean age of patients at data collection was 31 years (range, 7 months to 95 years), with an equal sex distribution. On linear regression analysis, there was a strong association between coagulation factor activity level and clinical bleeding severity for fibrinogen, factor (F) X, FXIII, and combined FV and FVIII deficiencies. A weaker association was present for FV and FVII deficiencies. There was no association between coagulation factor activity level and clinical bleeding severity for FXI. The coagulation factor activity levels that were necessary for patients to remain asymptomatic were: fibrinogen, > 100 mg dL−1; FV, 12 U dL−1; combined FV + VIII, 43 U dL−1; FVII, 25 U dL−1; FX, 56 U dL−1; FXI, 26 U dL−1; FXIII, 31 U dL−1. Moreover, coagulation factor activity levels that corresponded with Grade III bleeding were: undetectable levels for fibrinogen, FV and FXIII, < 15 U dL−1 for combined FV + VIII; < 8 U dL−1 for FVI; < 10 U dL−1 for FX; and < 25 U dL−1 for FXI. Conclusions: There is a heterogeneous association between coagulation factor activity level and clinical bleeding severity in different RBDs. A strong association is only observed in fibrinogen, FX and FXIII deficiencies.

21 May 2009 in Blood
Verified
Journal Article
Closed access
PDF file
DTDavid-Alexandre Trégouët
David-Alexandre Trégouët
SHSimon Heath
Simon Heath
NSNoémie Saut
Noémie Saut
CBChristine Biron-Andreani
Christine Biron-Andreani
JSJean-François Schved
Jean-François Schved
PMPierre-Emmanuel Morange
Pierre-Emmanuel Morange
Venous thromboembolism (VTE) is a complex disease that has a major genetic component of risk. To identify genetic factors that may modify the risk of VTE, we conducted a genome-wide association study by analyzing approximately 317 000 single nucleotide polymorphisms (SNPs) in 453 VTE cases and 1327 controls. Only 3 SNPs located in the FV and ABO blood group genes were found associated with VTE at a genome-wide significant level of 1.7 × 10−7. Detailed analysis of these SNPs in additional cohorts of more than 1700 cases and 1400 controls revealed that the association observed at the FV locus was the result of the increased risk mediated by the FV Leiden mutation, whereas O and A2 blood groups were found to be at lower risk for VTE. Apart from the FV and ABO loci, no other locus was found strongly associated with VTE. However, using this large cohort of subjects, we were able to replicate the mild effects of 2 nonsynonymous SNPs, rs1613662 in GP6 and rs13146272 in CYP4V2, recently suspected to be associated with VTE.

1 June 2013 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
GPGilles Pernod
Gilles Pernod
PAPierre Albaladejo
Pierre Albaladejo
AGAnne Godier
Anne Godier
CSCharles M. Samama
Charles M. Samama
SSSophie Susen
Sophie Susen
PSPierre SIE
Pierre SIE

1 January 2005 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
GMGuglielmo Mariani
Guglielmo Mariani
FHFalko H. Herrmann
Falko H. Herrmann
ADAlberto Dolce
Alberto Dolce
ABAngelika Batorova
Angelika Batorova
DEDaniela Etro
Daniela Etro
FAfor the International Factor VII Deficiency Study Group (see appendix)
for the International Factor VII Deficiency Study Group (see appendix)
Summary: To investigate the relationship between clinical phenotype, clotting activity (FVIIc) and FVII genotype, a multi-center study of factor VII (FVII) congenital deficiency with centralized genotyping and specific functional assays was carried out. FVII mutations characterized in patients (n=313) were extremely heterogeneous (103 different, 22 novel). Clinical phenotypes ranged from asymptomatic condition, including 15 homozygotes and 14 double heterozygotes, to patients with a severe disease char-acterized by life-threatening and disabling symptoms (CNS, GI bleeding and hemarthrosis) strongly associated with an early age of presentation. Based on type and number of symptoms we classified 90 'severe' (median FVIIc 1.4%, IQR [Interquartile Range] 0.9–3.8), 83 'moderate' (FVIIc 3%, IQR 1–21.7), and 140 'mild' bleeders (FVIIc 14%, IQR 3–31). The significantly different FVIIc levels, and the decreasing prevalence of homozygotes or double heterozygotes among severe (98%), moderate (84%) and mild (56%) bleeders, further support our classification. The excess of females among moderate bleeders (female/male ratio =2.6) is attributable to menorrhagia. There was no evidence for modulation of clinical features by frequent functional polymorphisms. Homozygotes for the same mutation (Ala294Val; 11125del C) with similar FVIIc and FXa generation levels, showed striking differences in clinical phenotypes. Our study depicts the ample clinical picture of this rare disorder, proposes a severity classification and provides arguments for the early management of the disease in the severe cases. Genotype-phenotype relationships indicate the presence of major environmental and/or extragenic components modulating expressivity of FVII deficiency.

1 January 2002 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
RDRaed Al Dieri
Raed Al Dieri
FPFlora Peyvandi
Flora Peyvandi
ESElena Santagostino
Elena Santagostino
MGMuriel Giansily
Muriel Giansily
PMPier Mannuccio Mannucci
Pier Mannuccio Mannucci
HHH. Coenraad Hemker
H. Coenraad Hemker
Summary: We investigated the relation between clotting factor concentration, the parameters of the thrombin generation curve (the thrombogram) and the severity of clinically observed bleeding in patients with congenital deficiency of prothrombin (n = 21), factor V (n = 22), factor VII (n = 22), factor X (n = 10), factor XI (n = 7) and factor XII (n = 6). The parameters used were: area under the curve (endogenous thrombin potential, ETP), peak concentration of thrombin attained and lag time before manifest formation.Peak height and ETP varied linearly with the concentration of prothrombin. For the other factors these parameters hyperbolically approached to the 100% limit with increasing clotting factor concentration. Half normal ETP was seen at about the following concentrations: prothrombin (50%), factor V (1%), factor VII (2%), factor X (5%) and factor XI (1%). As a rule, the peak height was somewhat more sensitive to clotting factor decrease than the ETP was.In all the patients with severe bleeding symptoms the ETP was less than 20% of normal. Bleeding tendency was absent or mild in patients with an ETP of 30% or higher. This value (except for prothrombin) is already obtained at concentrations of clotting factor of 1%-2%, which corroborates the clinical observation that a severe bleeding tendency is only seen in severe clotting factor deficiencies (less than 1%). The one exception was a patient with factor VII deficiency and severe bleeding, who showed a normal ETP value, albeit with a decreased peak height and a prolonged lag-time.